search

Active clinical trials for "Corneal Neovascularization"

Results 1-10 of 24

Corneal Crosslinking for Treatment of Corneal Neovascularization

Corneal Neovascularization

The study objective is to assess safety and efficacy of photo-activation of riboflavin for treatment of corneal neovascularization with or without concomitant inflammation and/or infection.

Recruiting6 enrollment criteria

Correlation Between a Novel Subset of Neutrophil and Corneal Neovascularization.

Corneal NeovascularizationNeutrophils

The purpose of this study is to determine whether a novel subset of neutrophils is correlated with corneal neovascularization in the patients suffered from ocular chemical injury.

Recruiting10 enrollment criteria

Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization

Corneal Neovascularization

The goal of this current study is to prospectively evaluate the influence of a single subconjunctival aflibercept injection on the regression of corneal neovascularization. Twenty patients with corneal neovascularization who are candidates for anti VEGF treatment (by the discretion of a corneal specialist) will be included in this study. The patients will be treated with a single subconjunctival injection of 0.08 ml aflibercept (25 mg/ml) in a single quarter of the conjunctiva, near the limbus in a proximity to the area of pathological neovascularization. Regression of neovascularization will be documented.

Terminated6 enrollment criteria

Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea

Corneal Neovascularization

The cornea is the clear front part of the eye. Corneal neovascularization, the excessive growth of blood vessels into the cornea, is a sight-threatening condition. Corneal neovascularization is also a well recognized risk factor for corneal graft failure. The current standard of care to prevent graft rejection includes use of topical steroids and medicines that suppress the immune system. These medicines do not address corneal neovascularization. The purpose of the study is to establish the safety and potential efficacy of subconjunctival injections of aflibercept (EYLEA® , marketed by Regeneron) injection in inducing regression of blood vessels growing into the cornea and promoting graft survival. This study is being conducted by Dr. Balamurali Ambati at the Moran Eye Center.

Terminated14 enrollment criteria

Topical IL-1-Ra for Treatment of Corneal Neovascularization

Corneal Neovascularization

The purpose of this study is to determine the effectiveness and safety of Interleukin-1-Receptor Antagonist eye drops for the treatment of corneal blood vessels.

Terminated13 enrollment criteria

Photodynamic Therapy With Verteporfin for Corneal Neovascularization

Corneal Neovascularization

Purpose: To investigate the efficacy of photodynamic therapy with verteporfin for the treatment of patients with corneal neovascularization. Design: Prospective, non-comparative case series. Participants: Eighteen eyes of 18 patients with stable corneal neovascularization who were refractory to conventional treatment. Methods: The patients were treated with photodynamic therapy with verteporfin (6 mg/m2). Five patients were treated following penetrating keratoplasty, and 2 patients were treated before penetrating keratoplasty. Best corrected visual acuity and anterior segment photography were performed before and after treatment. The length of cumulative blood vessels and area of corneal neovascularization were measured. Main outcome measures: Vascular occlusion, best corrected visual acuity, cumulative blood vessel length, and corneal neovascularization area.

Completed2 enrollment criteria

Topical Avastin for Treatment of Corneal Neovascularization

Corneal Neovascularization

The purpose of this study is to determine the effectiveness and safety of Topical Bevacizumab (Avastin) for treatment of corneal neovascularization.

Completed12 enrollment criteria

Randomized Study of Photodynamic Therapy Using Dihematoporphyrin in Patients With Corneal Neovascularization...

Corneal Neovascularization

OBJECTIVES: I. Demonstrate the safety and efficacy of dihematoporphyrin derivative (DHP) in laser photodynamic therapy (PDT) in patients with corneal neovascularization. II. Document the histopathologic mechanism of action in selected patients undergoing penetrating keratoplasty following PDT therapy for corneal neovascularization. III. Facilitate FDA product approval of DHP as a photosensitizing agent for laser treatment in these patients. IV. Explore the use of this photosensitizer for ocular and cutaneous basal cell and squamous cell carcinoma.

Completed4 enrollment criteria

A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival...

Corneal NeovascularizationCorneal Graft Failure

The goal of this study is to investigate whether using bevacizumab (Avastin®) is both safe and effective at decreasing the likelihood of a high-risk corneal graft rejection. Patients who are "high-risk" for rejection have blood vessels growing from the white of the eye into the cornea (clear, front region of the eye). The medication is used at the time of surgery and in the weeks following surgery. Participants have a 50/50 chance at receiving the active study medication or a placebo medication.

Completed21 enrollment criteria

Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization...

Corneal Neovascularization

Purpose: To determine the efficacy and safety of one commonly used VEGF inhibitor, bevacizumab (Avastin, Genentech), as a topical agent for the treatment of corneal neovascularization.

Completed24 enrollment criteria

Need Help? Contact our team!


We'll reach out to this number within 24 hrs